13F Holdings
中文EN

ARCT Arcturus Therapeutics Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1768224 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-68.7%
TTM net income YoY-30.8%
TTM EPS YoY-26.0%
Revenue 3-yr CAGR-53.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-311.2%
Net margin-285.9%
FCF margin-204.7%
EBITDA margin-302.9%

Returns

ROE-44.4%
ROA-35.1%
ROIC (approx.)-533.8%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets21.6%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue-0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$82.03M$152.31M$166.80M$206.00M$12.36M
R&D expense$112.21M$195.16M$192.13M$147.75M$173.76M
SG&A expense$46.08M$52.82M$52.87M$46.07M$41.45M
Operating income-$76.26M-$95.67M-$78.20M$12.18M-$202.85M
Pretax income-$65.78M-$80.94M-$27.89M$10.64M-$203.67M
Income tax—-$4,000$1.83M$1.29M—
Net income-$65.78M-$80.94M-$29.73M$9.35M-$203.67M
EBITDA-$73.23M-$92.12M-$75.25M$13.70M-$201.66M
EPS (basic)-2.40-3.00-1.120.35-7.74
EPS (diluted)-2.40-3.00-1.120.35-7.74
Weighted avg. shares (diluted)27.39M27.00M26.63M27.09M26.32M
Balance sheet
Cash & equivalents$230.91M$293.91M$292.00M$393.98M$372.57M
Receivables$5.56M$3.97M$32.06M$2.76M$3.37M
Current assets$241.45M$305.98M$386.59M$403.33M$378.96M
PP&E, net$6.74M$9.53M$12.43M$12.41M$5.64M
Total assets$271.15M$344.07M$429.40M$450.39M$392.81M
Current liabilities$36.38M$65.49M$81.99M$126.98M$99.54M
Short-term debt———$60.66M$22.47M
Long-term debt————$40.63M
Total debt————$63.11M
Total liabilities$57.16M$103.09M$150.89M$180.07M$164.60M
Shareholders' equity$213.99M$240.98M$278.51M$270.31M$228.21M
Net debt————-$309.46M
Shares outstanding28.41M27.00M26.83M26.55M26.37M
Cash flow statement
Operating cash flow-$74.27M-$59.75M-$18.10M$31.99M-$135.04M
Capital expenditure$230,000$648,000$2.90M$7.73M$3.41M
Free cash flow-$74.50M-$60.40M-$21.00M$24.27M-$138.45M
Investing cash flow-$230,000-$648,000-$2.90M-$7.73M-$3.41M
Financing cash flow$13.38M$5.42M-$24.09M-$2.86M$48.02M
Depreciation & amortization$3.02M$3.54M$2.96M$1.53M$1.19M
Stock-based compensation$25.41M$37.99M$34.65M$30.61M$28.91M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.